Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.
Also called NCT01923181
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 632 participants
- Sponsor
- Registry
-
NCT01923181 -
2012-004994-16
-
- Main results
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Bulgaria, Canada, Denmark, Germany, Israel, Italy, Malaysia, Serbia, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01923181. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2014-12-11 (actual). Results posted on 2019-11-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- oral placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01923181- Content hash
4f29ac34fb264c3736d84cf80fc9f89363fee530730ec1a13204f5fd439449aa